Answers are grounded in this paper and cite their sources.
The persistence of pathogenic CD8⁺ tissue-resident memory T (T RM ) cells in the synovium is considered a key contributor to disease relapse in rheumatoid arthritis (RA), but current therapies poorly target them. The RA autoreactive responses often target citrullinated vimentin (cV), an autoantigen against which autoantibodies are frequently detected in patients with RA, suggesting its key role in RA pathogenesis. We developed tolerogenic nanoparticles (cV-R-LNPs) to induce cV-specific regulatory T cells (Tregs) in vivo. In a novel arthritis mouse model that we established to recapitulate the cV-associated autoimmune features of RA. cV-R-LNP therapy demonstrated robust efficacy, potently suppressing arthritis scores and autoantibodies. These effects were associated with a marked reduction in the pathogenic synovial CD8⁺ T RM population and T RM phenotype reprogramming that suppressed IL-17 expression while enhancing IFN-γ expression. Our findings show that antigen-specific nanomedicine can disrupt established pathogenic tissue memory, offering a new strategy for durable, tolerance-driven remission in RA.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: